Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reversing Glucose and Lipid-mediated Vascular Dysfunction
NCT04832009Phase 1Recruiting
- Sponsor
- University of Kansas Medical Center
- Start
- May 2022
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ascorbic acid in vascular dysfunction (2 arms), sponsored by University of Kansas Medical Center. Primary endpoint: Efficacy of Infusion of Ascorbic Acid. Started May 2022; status: recruiting.
02
Drugs
ascorbic acid
03
Conditions
vascular dysfunction
Beyond the preview
Go deeper on NCT04832009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04832009.